Sumitomo Pharma America (SMPA), a Sumitomo Pharma company, is focused on areas of critical patient need in oncology, urology, women’s health, rare disease, psychiatry, neurology, and cell & gene therapies.
Innovation
Formed in 2023, SMPA is part of a group of companies working on innovative research and development activities to transform healthcare and improve the lives of people worldwide. This global ecosystem has a geographic footprint spanning Japan, the U.S., China, Canada, and Europe as well as talent, knowledge, and resources across a wide spectrum of technologies and therapeutic areas. Operating with data-driven insights, appropriate speed, and scientific rigor accelerating breakthroughs in oncology, urology, women’s health, rare disease, cell and gene therapy, psychiatry and neurology to bring treatment to patients sooner. A recent example of this is the July 2024 Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to an investigational small molecule for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with a KMT2A rearrangement, also known as mixed lineage leukemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m).
Patients
SMPA is dedicated to partnering with stakeholders to increase patient access to medicine. SMPA prides itself on its dedication to patients, rather than reducing them to the conditions they are managing. For female patients, they created a series of resources to help facilitate conversations when speaking with healthcare providers enhancing their experience and ultimately helping them find adequate support in the community.
Talent Development
At SMPA, fostering a healthy work environment and striving to improve the culture ensures its their staff feels valued and supported. Employees at SMPA are a part of a world-class team and vibrant culture where they can make an impact and grow personally and professionally.
Employees are encouraged to bring their whole selves to work and pursue their passion. SMPA values one another’s unique specialties and promotes collaboration and connection. They embrace individuality and care about the needs of their employees, enabling everyone to do their best work.
Social Responsibility
Social responsibility and associated philanthropic activities enrich a company’s culture by nourishing the spirit of teamwork, generosity, and caring. SMPA’s program is called One Team Cares and it aligns with a principle that is at the heart of everything the team does: caring for others by delivering for patients. These activities are both virtual and in person and include a day of service where teams and individuals have the option to take a full or half day away from work to undertake an activity to benefit a worthy cause of their choosing.
FINALISTS:
AstraZeneca
GSK
Lilly
Pfizer
Sumitomo Pharma America, Inc.
